Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
This study has been terminated.
(closed due to slow accrual)
Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Information provided by:
Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00126191
First received: August 2, 2005
Last updated: October 2, 2009
Last verified: October 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Estimated Study Completion Date: | June 2011 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |